Predicting Caregiver Anxiety and Depression From Patient Distress in Brain Tumor Dyads: Actor-Partner Interdependence Model

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-09-29 DOI:10.1002/cam4.71271

Anna-Maria Kisić, Maike K. Klett, Ralf Schaefer, Caterina Quente, Michael Sabel, Marion Rapp, André Karger

{"title":"Predicting Caregiver Anxiety and Depression From Patient Distress in Brain Tumor Dyads: Actor-Partner Interdependence Model","authors":"Anna-Maria Kisić, Maike K. Klett, Ralf Schaefer, Caterina Quente, Michael Sabel, Marion Rapp, André Karger","doi":"10.1002/cam4.71271","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Malignant brain tumors place significant physical, cognitive, and emotional strain on patients and caregivers. Psychosocial distress screening is part of standard care for patients, while caregiver screening remains challenging. This study examined the association of patient psychosocial distress at diagnosis with caregiver anxiety and depression over time.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This secondary analysis used data from a prospective, single-center, observational study of malignant brain tumor dyads. To assess the association of patient psychosocial distress at diagnosis (T0) with caregiver anxiety and depression at T0 and at 3 (T1) and 6 (T2) months post-diagnosis, the Actor-Partner Interdependence Model (APIM) was used.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Complete data from 58 dyads were included at T0, 43 at T1, and 41 at T2. Patient distress at T0 predicted caregiver depression at T1 (<i>β</i> = 0.310, <i>p</i> = 0.007) and T2 (<i>β</i> = 0.322, <i>p</i> = 0.005), and caregiver anxiety at T2 (<i>β</i> = 0.303, <i>p</i> = 0.020). Caregiver distress at T0 did not predict patient anxiety and depression at any time point. For both patients and caregivers, distress at T0 predicted their own anxiety and depression at T0 and their anxiety at T1. For caregivers, distress at diagnosis also predicted anxiety at T2.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Psychosocial distress experienced by patients with malignant brain tumors at diagnosis significantly predicts their caregivers' anxiety and depression over time. Caregivers at risk of increased anxiety and depression could therefore be identified by screening for patient distress. These findings also highlight the critical need for early psychosocial support for both patients and caregivers.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>Retrospectively registered in the German Clinical Trial Register (10 July 2024; DRKS00034637)</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 19","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477404/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71271","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Malignant brain tumors place significant physical, cognitive, and emotional strain on patients and caregivers. Psychosocial distress screening is part of standard care for patients, while caregiver screening remains challenging. This study examined the association of patient psychosocial distress at diagnosis with caregiver anxiety and depression over time.

Methods

This secondary analysis used data from a prospective, single-center, observational study of malignant brain tumor dyads. To assess the association of patient psychosocial distress at diagnosis (T0) with caregiver anxiety and depression at T0 and at 3 (T1) and 6 (T2) months post-diagnosis, the Actor-Partner Interdependence Model (APIM) was used.

Results

Complete data from 58 dyads were included at T0, 43 at T1, and 41 at T2. Patient distress at T0 predicted caregiver depression at T1 (β = 0.310, p = 0.007) and T2 (β = 0.322, p = 0.005), and caregiver anxiety at T2 (β = 0.303, p = 0.020). Caregiver distress at T0 did not predict patient anxiety and depression at any time point. For both patients and caregivers, distress at T0 predicted their own anxiety and depression at T0 and their anxiety at T1. For caregivers, distress at diagnosis also predicted anxiety at T2.

Conclusions

Psychosocial distress experienced by patients with malignant brain tumors at diagnosis significantly predicts their caregivers' anxiety and depression over time. Caregivers at risk of increased anxiety and depression could therefore be identified by screening for patient distress. These findings also highlight the critical need for early psychosocial support for both patients and caregivers.

Trial Registration

Retrospectively registered in the German Clinical Trial Register (10 July 2024; DRKS00034637)

Abstract Image

查看原文本刊更多论文

从患者痛苦预测脑肿瘤患者的照顾者焦虑和抑郁：行动者-伴侣相互依赖模型。

目的：恶性脑肿瘤给患者和护理人员带来巨大的身体、认知和情绪压力。心理社会困扰筛查是患者标准护理的一部分，而护理人员筛查仍然具有挑战性。本研究考察了患者在诊断时的社会心理困扰与护理者焦虑和抑郁的关系。方法：这项二级分析使用了一项前瞻性、单中心、恶性脑肿瘤双体观察性研究的数据。为了评估患者在诊断时（T0）的社会心理困扰与护理者在诊断后（T0）、3 （T1）和6 （T2）个月的焦虑和抑郁之间的关系，我们使用了行动者-伴侣相互依赖模型（APIM）。结果：T0时58对，T1时43对，T2时41对的完整数据。患者在T0时的痛苦可以预测T1 （β = 0.310, p = 0.007）和T2 （β = 0.322, p = 0.005）时照顾者的抑郁和T2时照顾者的焦虑（β = 0.303, p = 0.020）。护理人员在T0时的痛苦并不能预测患者在任何时间点的焦虑和抑郁。对于患者和护理人员来说，T0时的痛苦都能预测他们自己在T0时的焦虑和抑郁以及他们在T1时的焦虑。对于照顾者来说，诊断时的痛苦也预示着T2时的焦虑。结论：恶性脑肿瘤患者在诊断时所经历的社会心理困扰显著预测其照顾者随时间的焦虑和抑郁。因此，有增加焦虑和抑郁风险的护理人员可以通过筛查患者的痛苦来确定。这些发现还强调了对患者和护理人员提供早期社会心理支持的迫切需要。试验注册：回顾性注册在德国临床试验注册（2024年7月10日；DRKS00034637）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.